Dr. Charles Lynde

Dermatologist, Markham, ON

Dr. Charles Lynde is an Associate Professor in the Department of Medicine at the University of Toronto and holds a clinical teaching position at the University Health Network. He is the Medical Director of Lynde Institute for Dermatology and Lynderm Research. The Lynde Institute for Dermatology is a full service, interdisciplinary dermatology clinic. After receiving his B.Sc. and MD, degrees at the University of Toronto, Dr. Lynde studied Dermatology at the University of British Columbia and the University of Toronto, receiving his Board Certification (Canada and USA) in 1983.

Lynderm Research is under the guidance of Dr. Lynde as principal investigator for more than 30 years and over 300 clinical trials and is actively involved in the management of psoriasis, rosacea, onychomycosis, acne and atopic dermatitis among other dermatological conditions. Dr. Lynde has authored over 200 peer-reviewed articles.

Dr. Lynde has served in various roles for the CDA and AAD, including President of the Canadian Dermatology Association. He is the Editor of the CDA eBulletin and sits on the editorial boards of several journals and provides extensive consulting as well as being on the advisory boards of many pharmaceutical companies. Dr. Lynde is a frequent guest speaker both nationally and internationally at various dermatological conferences. Recognizing the need for external education he is committed to the training of new and current healthcare professionals in his community and residents through the university program.

9:00 AM - 9:45 AM Plenary Session 1

Thursday NOV 24, 2022

Opening & Drug Update

Learning objectives:

  1. To be familiar with the key dermatological therapeutics of 2022 and what’s in the pipeline for 2023 and beyond
  2. To translate this information into the changing dermatologic practice
9:45 AM - 10:00 PM Plenary Session 1

Thursday NOV 24, 2022

Optimizing Outcomes in Acne Management

In a medical encounter, there are two experts: the clinician, expert in disease and its management and the patient, expert in illness and their own circumstances. A therapeutic relationship is a journey recognizing the expertise of both. This presentation addresses practical aspects of initiating the acne care pathway representing the what, why, when and how aspects of treatment.

Learning objectives:

  1. Understand how to engage patients in a brief acne consultation
  2. List the critical questions that help direct your acne management plan
  3. Discuss essential aspects to explain at treatment initiation
10:00 AM - 10:15 PM Plenary Session 1

Thursday NOV 24, 2022

Management of Adult Female Acne

Learning objectives:

  1. Review hormones found in commonly used contraceptives and how they impact acne
  2. Update on new hormonal contraceptive agents
  3. Review non-contraceptive options for managing adult female acne
10:15 AM - 10:25 AM Plenary Session 1

Thursday NOV 24, 2022

Questions & Answers

11:05 AM - 11:50 AM Open Session

Thursday NOV 24, 2022

2022 recommendations for prevention of shingles in dermatology patients

Learning Objectives:

  • Recognize the clinical manifestations and complications of herpes zoster
  • List risk factors for Zoster and postherpetic neuralgia (PHN)
  • Recognize the benefit of vaccination to prevent zoster and postherpetic neuralgia
  • Discuss when and how to vaccinate your at risk patients against zoster

Summary:
The Canadian lifetime risk for zoster is 28%, and 50% over age 85. In addition to older age, a family history of zoster, immunosuppression and JAK inhibitors can also increase the risk for zoster. Zostavax was the first available zoster vaccine, but it was discontinued in Canada October 14, 2022. Shingrix is a non-live adjuvanted subunit vaccine which has approval for zoster prevention in immunocompetent individuals ≥ 50 years as well as immunocompromised individuals ≥ 18 years. Two doses of 0.5 ml reconstituted Shingrix IM are recommended given 2-6 months apart in immunocompetent individuals and may be given 1-2 months apart in immunocompromised individuals. It is highly efficacious (>90%) in immunocompetent individuals with a minimal decline in clinical efficacy and humoral and cellular immunity over 10 years of follow-up. It addition it has been shown to prevent postherpetic neuralgia and other zoster complications. The efficacy in immunocompromised individuals is comparable with persistent immunity for at least 1 year. Dermatologists should be proactive in recommending vaccination against zoster.

11:55 AM - 12:25 PM Open Presentation

Thursday NOV 24, 2022

New evidence supporting the benefits of ceramide-containing cleansers and moisturizers as adjunct therapy in acne vulgaris

Learning Objectives:

  1. Explore skin barrier dysfunction in acne
  2. Discuss the benefits and challenges of effective RX therapy in acne
  3. Present new data showcasing the benefits of ceramide-containing adjunct therapy

Summary/description of the session:
Skin barrier dysfunction plays a role in the pathology, development and severity of acne. Topical acne prescription therapy, while effective, can cause further damage to the skin barrier and lead to irritation and can negatively affect patient treatment adherence. In this presentation, new clinical evidence supporting the benefits of using ceramide-containing cleansers and moisturizers as adjunct therapy will be demonstrated.

1:20 PM - 1:50 PM Open Presentation

Thursday NOV 24, 2022

Alopecia Areata: A scoping review on quality of life, mental health, and work productivity.

Learning Objectives:

  1. Recognize the stigma and financial burden associated with alopecia areata (AA)
  2. Review the extent and determinants of quality-of-life burden associated with AA
  3. Understand the associated mental health comorbidities among AA patients of all ages
12:15 PM - 2:15 PM Advisory Board

Friday NOV 25, 2022

Sun Pharma Acne National Advisory Board

7:00 AM - 10:00 AM Advisory Board

Saturday NOV 26, 2022

Arcutis Working Group

4:40 PM - 4:45 PM Plenary Session 4

Saturday NOV 26, 2022

Questions & Answers

5:20 PM - 5:25 PM Plenary Session 4

Saturday NOV 26, 2022

Closing Comments

3:20 PM – 3:50 PM Novartis Open Presentation

Friday APR 8, 2022

Beyond the Skin: The Feasibility and Value of Systematic Screening for Psoriatic Arthritis


Dermatologists are the gatekeeper to identifying patients with early signs of PsA. However, many dermatologists do not routinely consider screening for possible signs and symptoms of psoriatic arthritis – a common psoriasis comorbidity that causes irreversible joint damage and aggravates co-morbidities.

 

The data from Phase 1 of the PsA Screening Project will be presented. In an initial assessment survey of 52 Canadian dermatologists, only 17% will screen their moderate-to-severe psoriasis patients for psoriatic arthritis at every follow-up visit. When screening for PsA, only 9% of respondents rely on a validated screening questionnaire. When PsA is suspected, over 50% of dermatologists will refer to a rheumatologist reflecting a need for greater comfort in managing PsA patients in dermatology practice and when appropriate, initiating a referral to rheumatologist. The PsA Screening Project had dermatologists from across the country screen patients using 3 different tools, to establish which tool type was preferred, and what barriers exist that prevent them from adequately screening.

 

Session Learning Objectives:

  • Recognize the impact of frequent screening for PsA on early detection
  • Demonstrate the value of using a standardized screening tool for PsA in dermatology practice
  • Consider best practices for implementation of systematic screening to improve patient outcomes
4:00 PM - 7:00 PM Sandoz Ad Board

Saturday APR 9, 2022

HYRIMOZ (adalimumab) Ad Board

9:00 AM - 1:00 PM La Roche-Posay Advisory Board

Sunday NOV 27, 2022

CaSMO Targeted Therapies Advisory Board